Extended Data Fig. 1: No small molecules specifically kill p53 mutant cancer cells or cell surface receptors upregulated on TP53 mutant cells.
From: Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs
a, Mean log2(fold-change) for compounds in the PRISM repurposing library (23Q2) on the viability of TP53 mutant (y-axis) and TP53 wild-type cell lines (x-axis) across DepMap. MDM2 inhibitors are boxed. There are no molecules >2-fold more toxic on average to p53Mut vs. p53WT cells in the PRISM repurposing library. b, Mean area under the curve (AUC) for compounds in the CTD2 library on the viability of TP53 mutant (y-axis) and TP53 wild-type cell lines (x-axis) across DepMap. There are no molecules with Δ(Mean AUC)Mut-WT < −0.5 in CTD2 screen. c, Mean mRNA expression (log2(TPM + 1)) for genes encoding cell surface proteins for TP53 mutant (y-axis) and TP53 wild-type cell lines across DepMap. d, p53 protein abundance (log2(RPPA Signal)) versus TP53 hotspot mutation status (WT, monoallelic, biallelic) across DepMap. e, p53 protein abundance (log2(RPPA Signal)) versus TP53 hotspot mutation status for select hotspot mutations (R273H, Y220C) across DepMap.
